Close Menu

NEW YORK (GenomeWeb) — OpGen reported after the close of the market Tuesday a 26 percent drop in its third quarter revenues, citing lower sales of its legacy QuickFISH rapid pathogen diagnostic products.

For the three months ended Sept. 30, OpGen's revenues fell to $552,221 from $745,114 in the same period the year before, pulled down by the decline in QuickFISH revenues, and in line with previously disclosed estimates.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sep
30
Sponsored by
LGC SeraCare Life Sciences

Non-invasive prenatal testing (NIPT) continues to expand globally to support maternal-fetal patient care. 

Oct
09
Sponsored by
PerkinElmer

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.